Literature DB >> 20400170

Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.

Nannan Zhou1, Li Fan, Hsu-Tso Ho, Beata Nowicka-Sans, Yongnian Sun, Yingjie Zhu, Yanhua Hu, Brian McAuliffe, Burt Rose, Hua Fang, Tao Wang, John Kadow, Mark Krystal, Louis Alexander, Richard Colonno, Pin-Fang Lin.   

Abstract

Treatment with HIV attachment inhibitors (AIs) can select for escape mutants throughout the viral envelope. We report on three such mutations: F423Y (gp120 CD4 binding pocket) and I595F and K655E (gp41 ectodomain). Each displayed decreased sensitivity to the AI BMS-488043 and earlier generation AIs, along with increased sensitivity to the broadly neutralizing antibodies 2F5 and 4E10, without affecting the rate of viral entry or sensitivity to the entry inhibitors AMD-3100 and Enfuvirtide. We also observed that I595F did not substantially increase envelope sensitivity to HIV-infected patient sera. Based on these observations, we propose that although F423Y, I595F and K655E may all affect the presentation of the 2F5 and 4E10 epitopes, natural immune mimicry is rare only for the I595F effect. Thus, it seems that in addition to restricting AI resistance development, incorporation of I595F into an appropriate vehicle could elicit a novel antiviral response to improve vaccine efficacy. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400170     DOI: 10.1016/j.virol.2010.03.033

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.

Authors:  Nannan Zhou; Beata Nowicka-Sans; Sharon Zhang; Li Fan; Jie Fang; Hua Fang; Yi-Fei Gong; Betsy Eggers; David R Langley; Tao Wang; John Kadow; Dennis Grasela; George J Hanna; Louis Alexander; Richard Colonno; Mark Krystal; Pin-Fang Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.

Authors:  Nicole Espy; Beatriz Pacheco; Joseph Sodroski
Journal:  Virology       Date:  2017-05-15       Impact factor: 3.616

3.  Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle.

Authors:  Rachel Van Duyne; Lillian S Kuo; Phuong Pham; Ken Fujii; Eric O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

Review 4.  The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors.

Authors:  Tao Wang; John F Kadow; Nicholas A Meanwell; Mark Krystal
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.

Authors:  Julia Gavrilyuk; Hitoshi Ban; Hisatoshi Uehara; Shannon J Sirk; Karen Saye-Francisco; Angelica Cuevas; Elise Zablowsky; Avinash Oza; Michael S Seaman; Dennis R Burton; Carlos F Barbas
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

Review 6.  Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

Authors:  Lu Lu; Fei Yu; Lifeng Cai; Asim K Debnath; Shibo Jiang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 7.  New Horizons in Structural Biology of Membrane Proteins: Experimental Evaluation of the Role of Conformational Dynamics and Intrinsic Flexibility.

Authors:  Robbins Puthenveetil; Eric T Christenson; Olga Vinogradova
Journal:  Membranes (Basel)       Date:  2022-02-16

Review 8.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.